BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 14612535)

  • 1. Alpha-methylacyl-CoA racemase as an androgen-independent growth modifier in prostate cancer.
    Zha S; Ferdinandusse S; Denis S; Wanders RJ; Ewing CM; Luo J; De Marzo AM; Isaacs WB
    Cancer Res; 2003 Nov; 63(21):7365-76. PubMed ID: 14612535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion of prostate cancer from hormone independency to dependency due to AMACR inhibition: involvement of increased AR expression and decreased IGF1 expression.
    Takahara K; Azuma H; Sakamoto T; Kiyama S; Inamoto T; Ibuki N; Nishida T; Nomi H; Ubai T; Segawa N; Katsuoka Y
    Anticancer Res; 2009 Jul; 29(7):2497-505. PubMed ID: 19596919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
    Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Branched fatty acids in dairy and beef products markedly enhance alpha-methylacyl-CoA racemase expression in prostate cancer cells in vitro.
    Mobley JA; Leav I; Zielie P; Wotkowitz C; Evans J; Lam YW; L'Esperance BS; Jiang Z; Ho SM
    Cancer Epidemiol Biomarkers Prev; 2003 Aug; 12(8):775-83. PubMed ID: 12917210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
    Luo J; Zha S; Gage WR; Dunn TA; Hicks JL; Bennett CJ; Ewing CM; Platz EA; Ferdinandusse S; Wanders RJ; Trent JM; Isaacs WB; De Marzo AM
    Cancer Res; 2002 Apr; 62(8):2220-6. PubMed ID: 11956072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP.
    Swinnen JV; Esquenet M; Goossens K; Heyns W; Verhoeven G
    Cancer Res; 1997 Mar; 57(6):1086-90. PubMed ID: 9067276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
    Murthy S; Agoulnik IU; Weigel NL
    Prostate; 2005 Sep; 64(4):362-72. PubMed ID: 15754350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
    Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A nonclassic CCAAT enhancer element binding protein binding site contributes to alpha-methylacyl-CoA racemase expression in prostate cancer.
    Zha S; Isaacs WB
    Mol Cancer Res; 2005 Feb; 3(2):110-8. PubMed ID: 15755877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The androgen receptor pathway is by-passed in prostate cancer cells generated after prolonged treatment with bicalutamide.
    Hobisch A; Fritzer A; Comuzzi B; Fiechtl M; Malinowska K; Steiner H; Bartsch G; Culig Z
    Prostate; 2006 Mar; 66(4):413-20. PubMed ID: 16302272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of SULT2B1b expression alters effects of 3beta-hydroxysteroids on cell proliferation and steroid hormone receptor expression in human LNCaP prostate cancer cells.
    He D; Falany CN
    Prostate; 2007 Sep; 67(12):1318-29. PubMed ID: 17626250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells.
    Shigemura K; Sung SY; Kubo H; Arnold RS; Fujisawa M; Gotoh A; Zhau HE; Chung LW
    Prostate; 2007 May; 67(7):722-31. PubMed ID: 17342749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of monoclonal antibody (P504S) and polyclonal antibody to alpha methylacyl-CoA racemase (AMACR) in the work-up of prostate cancer.
    Kunju LP; Chinnaiyan AM; Shah RB
    Histopathology; 2005 Dec; 47(6):587-96. PubMed ID: 16324196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
    Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
    Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
    Schostak M; Miller K; Krause H; Schrader M; Kempkensteffen C; Kollermann J
    Cancer Detect Prev; 2006; 30(5):449-54. PubMed ID: 17067752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.
    Malinowska K; Neuwirt H; Cavarretta IT; Bektic J; Steiner H; Dietrich H; Moser PL; Fuchs D; Hobisch A; Culig Z
    Endocr Relat Cancer; 2009 Mar; 16(1):155-69. PubMed ID: 19011039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen receptor-mediated repression of novel target genes.
    Prescott J; Jariwala U; Jia L; Cogan JP; Barski A; Pregizer S; Shen HC; Arasheben A; Neilson JJ; Frenkel B; Coetzee GA
    Prostate; 2007 Sep; 67(13):1371-83. PubMed ID: 17624924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
    Koochekpour S; Lee TJ; Wang R; Culig Z; Delorme N; Caffey S; Marrero L; Aguirre J
    Prostate; 2007 Feb; 67(2):178-89. PubMed ID: 17044040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines.
    Maria McCrohan A; Morrissey C; O'Keane C; Mulligan N; Watson C; Smith J; Fitzpatrick JM; Watson RW
    Cancer; 2006 Jun; 106(12):2743-52. PubMed ID: 16703599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
    J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.